CGS-authored
A University of California Berkeley economics professor has done an analysis of the financial returns likely to come to California from stem cell research--and he said they will likely be a small fraction of what proponents of state-funded stem-cell research have estimated.
Dr. Richard Gilbert originally published his report--titled "Dollars for Genes: Revenue Generation by the California Institute for Regenerative Medicine"--in the Berkeley Technology Law Journal in June. It finds that the state will likely make only minimal financial returns on any stem cell research it funds via the California Institute for Regenerative Medicine (CIRM).
"The study finds that stem cell research could be good for the people of California," Gilbert said. "But it is probably not going to make a lot of money for the people of California."
At issue is a September 2004 analysis produced by Dr. Laurence Baker, an associate professor of the Stanford University School of Medicine, and Bruce Deal, managing partner of the Analysis Group, a consulting firm based in Menlo Park. That paper, "Economic Impact Analysis: Proposition 71 California Stem Cell Research and Cures...